Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan

Table 3 Logistic regression analysis to investigate the risk factors for negative neutralizing activity against the Omicron variant after booster vaccination

	Unadjusted		Adjusted
Characteristics	OR (95% CI)	p-value	OR (95% CI)	p-value
Age, (years)	1.010 (0.987, 1.034)	0.390	0.996 (0.963, 1.031)	0.831
Sex, female *1	0.903 (0.394, 2.071)	0.809
Booster vaccination type, mRNA-1273 (Moderna) *2	1.630 (0.716, 3.711)	0.383	1.123 (0.421, 2.994)	0.817
Period from the first dose to booster dose, (days)	0.999 (0.976, 1.023)	0.950
Period from the booster dose to blood sampling, (days)	1.008 (0.982, 1.035)	0.543
ECOG-PS	1.168 (0.922, 1.481)	0.198	1.098 (0.744, 1.620)	0.639
No. of comorbidities	1.139 (0.868, 1.495)	0.348
Immunosuppression	6.837 (0.806, 57.996)	0.078	6.226 (0.705, 54.956)	0.100
Serum albumin level (g/dL)	0.613 (0.261, 1.441)	0.262	0.783 (0.176, 3.489)	0.749
e-GFR (mL/min per 1·73 m²)	1.012 (0.994, 1.031)	0.184
HbA1c (%)	0.803 (0.384, 1.681)	0.560

Abbreviations: ECOG-PS Eastern Cooperative Oncology Group Performance Status Scale, e-GFR, Estimated glomerular filtration rate, HbA1c Glycated hemoglobin
^*1 The dummy variable "sex" was coded as male = 0 and female = 1
^*2 The dummy variable "Booster vaccination type" was coded as BNT162b2 (Pfizer-BioNTech) = 0 and mRNA-1273 (Moderna) = 1

ISSN: 1742-4933